Vericiguat Improves Cardiac Remodelling and Function in Rats with Doxorubicin-Induced Cardiomyopathy
ESC Heart Failure · 01.06.2025 · 12 (3) · 1807-1817
DOI: 10.1002/ehf2.15186 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESC Heart Failure, online erschienen am 17.01.2025. Verfasst von Wen Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Fujian Medical University, Department of Cardiology, Affiliated Hospital of Putian University, Putian, China. Hauptthemen laut MEDLINE: Cardiomyopathies, Ventricular Remodeling, Pyrimidines, Ventricular Function, Left. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Fujian Provincial Health Technology Project.
Abstract (Originalsprache)
Purpose
Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in patients with doxorubicin (DOX)-induced cardiomyopathy (DIC). In this study, we investigated the effects of vericiguat on cardiac structure and function in rats with DIC as well as their potential mechanisms of action.
Methods
DIC rats were established by intraperitoneal injection of DOX (1 mg/kg) twice a week for 6 weeks, followed by intragastric administration of vericiguat 1 mg/kg/day or an equal volume of normal saline for 8 weeks. Cardiac histology and function, circulating levels of amino-terminal pro-B-type natriuretic peptide (NT-proBNP), nitric oxide (NO), and oxidative indices, as well as myocardial cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signalling, oxidative and apoptosis-associated protein were measured.
Results
Compared with the control group, rats treated with DOX exhibited significantly increased heart size, reduced systolic function and elevated plasma levels of NT-proBNP. Histological findings revealed myocardial cell atrophy, fibrosis and apoptosis. Vericiguat treatment effectively reversed DOX-induced cardiac remodelling and improved systolic function. Mechanistically, Vericiguat attenuated the inhibitory effects of DOX on the myocardial cGMP-PKG axis and nuclear factor erythroid 2-related factor 2 (Nrf2) protein, thereby alleviating oxidative stress and apoptosis.
Conclusions
Vericiguat improved cardiac remodelling and contractile function in rats with DIC through upregulation of cGMP-PKG signalling and inhibition of oxidative stress and myocardial apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Fujian Medical University, Department of Cardiology, Affiliated Hospital of Putian University, Putian, China.
Förderung
- Natural Science Foundation of Fujian Province
- National Natural Science Foundation of China
- Fujian Provincial Health Technology Project
- Education and Scientific Research Project of Young and Middle-Aged Teachers in Fujian Education Department
Zitieren
APA
Chen, W., Wu, Y., Li, W., Song, M., Xu, K., Wu, M., & Lin, L. (2025). Vericiguat Improves Cardiac Remodelling and Function in Rats with Doxorubicin-Induced Cardiomyopathy. ESC Heart Failure, 12(3), 1807-1817. https://doi.org/10.1002/ehf2.15186
Vancouver
Chen W, Wu Y, Li W, Song M, Xu K, Wu M, et al. Vericiguat Improves Cardiac Remodelling and Function in Rats with Doxorubicin-Induced Cardiomyopathy. ESC Heart Failure. 2025;12(3):1807-1817. doi:10.1002/ehf2.15186
BibTeX
@article{Chen2025,
author = {Chen, Wen and Wu, Ying and Li, Wei and Song, Meiyan and Xu, Kaizu and Wu, Meifang and Lin, Liming},
title = {Vericiguat Improves Cardiac Remodelling and Function in Rats with Doxorubicin-Induced Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2025},
volume = {12},
number = {3},
pages = {1807--1817},
doi = {10.1002/ehf2.15186}
}
EUVIMED